18 F-FDG PET/CT Imaging of a Rare Rectal Extraluminal Metastasis From Pulmonary Sarcomatoid Carcinoma.

Clin Nucl MedJun 12, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)

Qiyun Xu, Huiqin Wu, Juan Zhong et al.

✦ AI-curated · Sources linked

Case in brief

A patient with pulmonary sarcomatoid carcinoma underwent 18F-FDG PET/CT, which detected a rectal metastasis. The reported lesion was extraluminal, identifying an uncommon metastatic site in this aggressive form of non-small cell lung cancer. The abstract does not provide further clinical findings, diagnostic confirmation details, treatment, or outcome.

What made this case unusual

The metastasis was rectal and extraluminal, an uncommon site and presentation for pulmonary sarcomatoid carcinoma.

Diagnostic / clinical pearl

Consider that pulmonary sarcomatoid carcinoma may involve uncommon metastatic sites; in this case, 18F-FDG PET/CT detected rectal involvement.

Source

PubMed · PMID 42341192

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.